Sign up to save your podcasts
Or
Share Managing Toxicities of EGFR Inhibitors: Afatinib, Amivantamab-Lazertinib, Osimertinib
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Managing Toxicities of EGFR Inhibitors: Afatinib, Amivantamab-Lazertinib, Osimertinib
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations.
In this informative discussion, they covered:
• The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib.
• Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions.
• Strategies for managing these side effects to improve patient quality of life and treatment adherence.
• Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches.
Youtube: https://youtu.be/v6fb6nx0YY4
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!
View all episodes
By Oncology Brothers
4.8
3939 ratings
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations.
In this informative discussion, they covered:
• The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib.
• Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions.
• Strategies for managing these side effects to improve patient quality of life and treatment adherence.
• Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches.
Youtube: https://youtu.be/v6fb6nx0YY4
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
322 Listeners
Journal of Clinical Oncology (JCO) Podcast
41 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
505 Listeners
ASCO Daily News
60 Listeners
Core IM | Internal Medicine Podcast
1,116 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
362 Listeners
Lung Cancer Considered
28 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners